Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Myalgia, Nasal congestion, Neck pain, Pain, Vaccination site pain
Clinical narrative: Injection site soreness and muscle pain.; Injection site soreness and muscle pain.; Severe headache; moderate neck ache; body aches; joints.; Chest tightness; Nasal congestion; Significant fatigue; malaise; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 65-year-old female patient (not pregnant) received bnt162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), on 09Oct2023 at 12:15 as dose 1, single (Lot number: HG4629) at the age of 65 years, in right arm for covid-19 immunisation; for covid-19 immunisation. The patient's relevant medical history included: "Eczema" (unspecified if ongoing); "allergic rhinitis" (unspecified if ongoing); "IBS" (unspecified if ongoing); "known allergies: Penicillin" (unspecified if ongoing); "known allergies: sulfa" (unspecified if ongoing); "known allergies: latex" (unspecified if ongoing); "Known allergies: All topical antibiotics" (unspecified if ongoing). The patient's concomitant medications were not reported. Past drug history included: Erythromycin, reaction(s): "known allergies: erythromycin"; Tetracycline, reaction(s): "known allergies: tetracycline"; Codeine, reaction(s): "known allergies: codeine". Vaccination history included: Covid-19 vaccine (DOSE 4 (BOOSTER), SINGLE; Manufacturer Unknown), for Covid-19 Immunization; Covid-19 vaccine (DOSE 3(BOOSTER), SINGLE; Manufacturer Unknown), for Covid-19 Immunization; Covid-19 vaccine (DOSE 2, SINGLE ; Manufacturer Unknown), for Covid-19 Immunization; Covid-19 vaccine (DOSE 1, SINGLE ; Manufacturer Unknown), for Covid-19 Immunization. The following information was reported: CHEST DISCOMFORT (non-serious) with onset 09Oct2023 at 14:30, outcome "recovering", described as "Chest tightness"; VACCINATION SITE PAIN (non-serious), MYALGIA (non-serious) all with onset 09Oct2023 at 14:30, outcome "recovering" and all described as "Injection site soreness and muscle pain."; NASAL CONGESTION (non-serious) with onset 09Oct2023 at 14:30, outcome "recovering"; HEADACHE (non-serious) with onset 09Oct2023 at 14:30, outcome "recovering", described as "Severe headache"; FATIGUE (non-serious) with onset 09Oct2023 at 14:30, outcome "recovering", described as "Significant fatigue"; PAIN (non-serious) with onset 09Oct2023 at 14:30, outcome "recovering", described as "body aches"; ARTHRALGIA (non-serious) with onset 09Oct2023 at 14:30, outcome "recovering", described as "joints."; MALAISE (non-serious) with onset 09Oct2023 at 14:30, outcome "recovering"; NECK PAIN (non-serious) with onset 09Oct2023 at 14:30, outcome "recovering", described as "moderate neck ache". Therapeutic measures were not taken as a result of vaccination site pain, myalgia, headache, neck pain, pain, arthralgia, chest discomfort, nasal congestion, fatigue, malaise. Additional information: There are no other vaccine in four weeks. There was no COVID prior vaccination and no COVID tested post vaccination.  The information on the batch/lot number for bnt162b2 omi xbb.1.5  has been requested and will be submitted if and when received.